Drug intelligence / Profile preview

Flexogan

Development stage: Unknown
Lead developer: UMeWorld
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Topical

Overview

Flexogan is a topical analgesic cream developed by AlphaRx Inc. for the temporary relief of muscle, joint, and arthritis pain. The product is a combination formulation containing camphor, menthol, and methyl salicylate. It utilizes AlphaRx's proprietary Bioadhesive Colloidal Dispersion (BCD) technology, a nano-delivery system designed to enhance the speed, depth, and sustained duration of drug penetration through the skin. Flexogan was approved for over-the-counter (OTC) sale in Canada and received marketing approval in Hong Kong in 2006. It is typically applied directly to the affected area 3-4 times daily.

Brand names: Flexogan

Targets

TRPM8 (Transient receptor potential cation channel subfamily M member 8)TRPV3 (Transient receptor potential vanilloid subtype 3)COX

Beyond the preview

Go deeper on Flexogan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flexogan.

Explore the full profile